Cargando…
Analysis of Yes-Associated Protein-1 (YAP1) Target Gene Signature to Predict Progressive Breast Cancer
Breast cancers are treated according to the ER/PR or HER2 expression and show better survival outcomes with targeted therapy. Triple-negative breast cancers (TNBCs) with a lack of expression of ER/PR and HER2 are treated with systemic therapy with unpredictable responses and outcomes. It is essentia...
Autores principales: | Venkatasubramanian, Gomathi, Kelkar, Devaki A., Mandal, Susmita, Jolly, Mohit Kumar, Kulkarni, Madhura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999906/ https://www.ncbi.nlm.nih.gov/pubmed/35407556 http://dx.doi.org/10.3390/jcm11071947 |
Ejemplares similares
-
Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer
por: Kulkarni, Apurv, et al.
Publicado: (2020) -
Inhibition of Yes-Associated Protein-1 (YAP1) Enhances the Response of Invasive Breast Cancer Cells to the Standard Therapy
por: Guimei, Maha, et al.
Publicado: (2020) -
An Integrative Systems Biology Approach Identifies Molecular Signatures Associated with Gallbladder Cancer Pathogenesis
por: Roy, Nabanita, et al.
Publicado: (2021) -
Promoter methylation of yes-associated protein (YAP1) gene in polycystic ovary syndrome
por: Jiang, Li-Le, et al.
Publicado: (2017) -
JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis
por: Tomlinson, V, et al.
Publicado: (2010)